Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor.

ABSTRACT:

Unlabelled

Despite a recent shift away from anti-insulin-like growth factor I receptor (IGF-IR) therapy, this target has been identified as a key player in the resistance mechanisms to various conventional and targeted agents, emphasizing its value as a therapy, provided that it is used in the right patient population. Molecular markers predictive of antitumor activity of IGF-IR inhibitors remain largely unidentified. The aim of this study is to evaluate the impact of insulin receptor (IR) isoforms on the antitumor efficacy of cixutumumab, a humanized mAb against IGF-IR, and to correlate their expression with therapeutic outcome. The data demonstrate that expression of total IR rather than individual IR isoforms inversely correlates with single-agent cixutumumab efficacy in pediatr

SUBMITTER: Forest A 

PROVIDER: S-EPMC4685019 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature